Fewer than 10% of patients eligible to benefit from obesity jabs like Wegovy are able to get them, caution the WHO as it releases its first recommendations on the drugs.
With in excess of 1,000,000,000 people worldwide now living with obesity, it is advocating for increased and just availability to these injectable treatments.
According to estimates, over two billion are projected to be living with obesity by 2030 unless action is taken.
"The new guidelines recognises that excess weight is a lifelong illness that can be managed with comprehensive and continuous treatment," stated its chief Tedros Adhanom Ghebreyesus.
Significant expense, limited production capacity, and distribution challenges are key hurdles to widespread access to the treatments that can help people shift substantial body mass, explains the organization.
Skinny Jab Scarcity
Despite the current most optimistic scenario, the production of such drugs might only reach around 100 million people – less than 10% of eligible patients, as stated by the WHO.
The guideline encourages nations and manufacturers to widen access, via measures such as licensing agreements.
Exclusive production rights on a key compound – the main component of the drug Wegovy – is scheduled to end in a number of countries in 2026.
The Way Weight-Loss Injections Work
GLP-1 drugs imitate a body's own hormone to slow digestion, curb appetite and enhance feelings of fullness so people consume fewer calories.
Individuals usually start to lose weight in the initial weeks of commencing the regular doses.
Evidence suggests patients may regain a significant portion a year later of stopping the drug, as their typical hunger resume.
Being above a healthy weight raises your chance for contracting medical conditions, like diabetes, cardiovascular issues, brain attack, and some cancers.
Excess weight concerns individuals in countries worldwide and was linked to over three and a half million fatalities worldwide in 2024, per the health agency.
